This review provides an update on the diagnosis and management of head and neck hard tissue sarcomas, a rare and heterogeneous group of tumors.
Management of these rare sarcomas should remain individualized; leaves open the need for prospective trials to standardize care.
Head and neck hard tissue sarcomas form a rare group of mesenchymal-derived tumours that comprise less than 1% of all head and neck neoplasms. Hard tissue sarcomas account for 20% of head and neck sarcomas and they form a heterogeneous group with a diverse origin. Unlike head and neck soft-tissue sarcomas, they have lower recurrence and mortality rates. In this study, we review the current management of head and neck hard tissue sarcomas.
No takes yet. Share an insight, caveat, or question.
Tudor‐Green et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: